- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04856891
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis (EoDyssey)
December 13, 2023 updated by: Allakos Inc.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard Therapies
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis.
Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Allakos Investigational Site
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Allakos Investigational Site
-
-
California
-
Chula Vista, California, United States, 91910
- Allakos Investigational Site
-
Lomita, California, United States, 90717
- Allakos Investigational Site
-
-
Colorado
-
Wheat Ridge, Colorado, United States, 80033
- Allakos Investigational Site
-
-
Connecticut
-
Bristol, Connecticut, United States, 06010
- Allakos Investigational Site
-
Hamden, Connecticut, United States, 06518
- Allakos Investigational Site
-
-
Florida
-
Brandon, Florida, United States, 33511
- Allakos Investigational Site
-
Edgewater, Florida, United States, 32132
- Allakos Investigational Site
-
Jacksonville, Florida, United States, 32256
- Allakos Investigational Site
-
Kissimmee, Florida, United States, 34741
- Allakos Investigational Site
-
Lakewood Ranch, Florida, United States, 34211
- Allakos Investigational Site
-
New Port Richey, Florida, United States, 34653
- Allakos Investigational Site
-
Ponte Vedra, Florida, United States, 32081
- Allakos Investigational Site
-
-
Louisiana
-
Crowley, Louisiana, United States, 70526
- Allakos Investigational Site
-
-
Nevada
-
Reno, Nevada, United States, 89511
- Allakos Investigational Site
-
-
New Jersey
-
Florham Park, New Jersey, United States, 07932
- Allakos Investigational Site
-
-
New York
-
Great Neck, New York, United States, 11023
- Allakos Investigational Site
-
-
North Carolina
-
Concord, North Carolina, United States, 28027
- Allakos Investigational Site
-
Durham, North Carolina, United States, 27710
- Allakos Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Allakos Investigational Site
-
Cincinnati, Ohio, United States, 45231
- Allakos Investigational Site
-
Dayton, Ohio, United States, 45415
- Allakos Investigational Site
-
Mentor, Ohio, United States, 44094
- Allakos Investigational Site
-
-
South Carolina
-
Greenwood, South Carolina, United States, 29646
- Allakos Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- Allakos Investigational Site
-
Hermitage, Tennessee, United States, 37076
- Allakos Investigational Site
-
Hixson, Tennessee, United States, 37343
- Allakos Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78745
- Allakos Investigational Site
-
Cedar Park, Texas, United States, 78613
- Allakos Investigational Site
-
Fort Worth, Texas, United States, 76104
- Allakos Investigational Site
-
Lubbock, Texas, United States, 79410
- Allakos Investigational Site
-
San Antonio, Texas, United States, 78229
- Allakos Investigational Site
-
Southlake, Texas, United States, 76092
- Allakos Investigational Site
-
Webster, Texas, United States, 77598
- Allakos Investigational Site
-
-
Utah
-
Ogden, Utah, United States, 84405
- Allakos Investigational Site
-
Salt Lake City, Utah, United States, 84132
- Allakos Investigational Site
-
Sandy, Utah, United States, 84092
- Allakos Investigational Site
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Allakos Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provide written informed consent.
- Male or female aged ≥18 and ≤80 years at the time of signing the informed consent for entry.
- Baseline endoscopic biopsy with ≥30 eosinophils/hpf in 3 hpf in the duodenum, as determined by central histology assessment of biopsies collected during the screening EGD + colonoscopy, without any other significant cause for the eosinophilia.
- Completion of at least 4 daily PRO questionnaires per week for a minimum of 3 weeks during screening.
- A weekly average score of abdominal pain, nausea, or diarrhea ≥3 on the PRO questionnaire (score from 0-10) for at least 2 weeks of screening and a weekly average TSS of ≥10 for at least 2 weeks of screening.
- Inadequate or loss of response to, or intolerant to standard therapies for EoD symptoms, which could include PPI, antihistamines, systemic or topical corticosteroids, and/or diet, among others.
- If patient is on pre-existing dietary restrictions, willingness to maintain dietary restrictions throughout the study.
- Willing and able to comply with all study procedures and visit schedule including follow-up visits.
- Female patients must be either post-menopausal for at least 1 year with FSH level >30 MIU/mL at screening or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from screening until the end of the study, or for 120 days following the last dose of study drug, whichever is longer. Male patients with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until the end of the study or for 120 days following the last dose of study drug, whichever is longer. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or later menstrual period) at any time during study participation.
Exclusion Criteria:
- Use of systemic or topical corticosteroids exceeding the equivalent of 10 mg/day prednisone within 4 weeks prior to the screening visit.
- Baseline endoscopic biopsy with ≥30 eosinophils/hpf in 5 hpf in the gastric mucosa as determined by central histology assessment of biopsies collected during the screening EGD.
- Change in the dose of corticosteroids (systemic or topical), PPI, leukotrienes, or diet therapy within 4 weeks prior to the screening visit.
- Treatment with any immunosuppressive or immunomodulatory drugs that may interfere with the study within 12 weeks prior to the screening visit.
- Prior exposure to AK002 or known hypersensitivity to any constituent of the study drug.
- Active Helicobacter pylori infection, unless treated and confirmed to be negative by repeat EGD (for baseline eosinophil count) prior to randomization and symptoms remain consistent.
- History of inflammatory bowel disease, other chronic inflammatory diseases in the colon (with the exception of eosinophilic colitis), celiac disease, achalasia, or esophageal surgery.
- History of bleeding disorders and/or esophageal varices.
- Other causes of duodenal eosinophilia or eosinophilic granulomatosis with polyangiitis.
- Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
- Presence of an abnormal laboratory value considered to be clinically significant by the Investigator.
- Any disease, condition (medical or surgical), or cardiac abnormality, which, in the opinion of the Investigator, would place the patient at increased risk.
- History of malignancy, except carcinoma in situ, early stage prostate cancer, or non-melanoma skin cancers. However, patients with cancers that have been in remission for more than 5 years and are considered cured can be enrolled.
- Treatment for a clinically significant helminthic parasitic infection within 6 months of screening.
- Positive helminthic infection on Ova and Parasite (O&P) test.
- Seropositive for Strongyloides stercoralis at screening.
- Seropositive for HIV or hepatitis at screening, except for vaccinated patients or patients with past but resolved hepatitis, at screening.
- Vaccination with live attenuated vaccines within 30 days prior to initiation of treatment in the study, during the treatment period, or vaccination expected within 5 half-lives (4 months) of study drug administration. This exclusion criterion does not apply to all types and formulations of vaccines (including live attenuated vaccines) authorized by FDA or other regulatory authority for the prevention of COVID-19, which may be administered before, during, or after the study.
- Participation in a concurrent interventional study with the last intervention occurring within 30 days prior to study drug administration (or 90 days or 5 half-lives, whichever is longer, for biologic products).
- Known history of alcohol, drug, or other substance abuse or dependence that is considered by the Investigator to be ongoing and clinically significant.
- Any other reason that in the opinion of the Investigator or the Medical Monitor makes the patient unsuitable for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3.0 mg/kg of Lirentelimab (AK002)
Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.
|
Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
Other Names:
|
Placebo Comparator: Placebo
Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Tissue Eosinophil Responders at Week 24
Time Frame: At Week 24
|
A tissue eosinophil responder is defined as mean eosinophil count <=15 cells/HPF in 3 duodenal HPFs
|
At Week 24
|
Change in PRO Total Symptom Score (TSS) From Baseline to Weeks 23-24
Time Frame: Baseline to Weeks 23 - 24
|
The PRO Total Symptom Score (TSS) is a patient reported outcome (PRO) questionnaire comprises the following 6 symptoms: Abdominal pain intensity, Nausea intensity, Fullness before meal intensity, Loss of appetite intensity, Bloating intensity, and Abdominal cramping intensity.
TSS scores can range from 0 to 60, with a lower score indicating less- severe symptoms.
|
Baseline to Weeks 23 - 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Tissue Eosinophils From Baseline to Week 24
Time Frame: Baseline to Week 24
|
Tissue eosinophil count obtained in biopsy specimens from the duodenum using esophago-gastro-duodenoscopy (EGD)
|
Baseline to Week 24
|
Subjects Achieving Eosinophils Count ≤1 Cell/Hpf in 3 Highest Duodenal Hpf at Week 24
Time Frame: At Week 24
|
Tissue eosinophil count obtained in biopsy specimens from the duodenum using esophago-gastro-duodenoscopy (EGD)
|
At Week 24
|
Number of Treatment Responders
Time Frame: At Weeks 23-24 and Week 24, Respectively
|
Treatment responders defined by >30% improvement in TSS and eosinophil count ≤15 cells per hpf in 3 duodenal hpf
|
At Weeks 23-24 and Week 24, Respectively
|
Subjects Who Achive ≥50% Reduction in TSS From Baseline to Weeks 23-24
Time Frame: At Weeks 23-24
|
The PRO Total Symptom Score (TSS) is a patient reported outcome (PRO) questionnaire comprises the following 6 symptoms: Abdominal pain intensity, Nausea intensity, Fullness before meal intensity, Loss of appetite intensity, Bloating intensity, and Abdominal cramping intensity.
TSS scores can range from 0 to 60, with a lower score indicating less- severe symptoms.
|
At Weeks 23-24
|
Subjects Who Achieve ≥70% Reduction in TSS From Baseline to Weeks 23-24
Time Frame: At Weeks 23-24
|
The PRO Total Symptom Score (TSS) is a patient reported outcome (PRO) questionnaire comprises the following 6 symptoms: Abdominal pain intensity, Nausea intensity, Fullness before meal intensity, Loss of appetite intensity, Bloating intensity, and Abdominal cramping intensity.
TSS scores can range from 0 to 60, with a lower score indicating less- severe symptoms.
|
At Weeks 23-24
|
Percent Change in Weekly TSS Over Time Using MMRM
Time Frame: Baseline to Week 24
|
The PRO Total Symptom Score (TSS) is a patient reported outcome (PRO) questionnaire comprises the following 6 symptoms: Abdominal pain intensity, Nausea intensity, Fullness before meal intensity, Loss of appetite intensity, Bloating intensity, and Abdominal cramping intensity.
TSS scores can range from 0 to 60, with a lower score indicating less- severe symptoms.
|
Baseline to Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Craig Paterson, MD, Allakos Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 20, 2021
Primary Completion (Actual)
June 14, 2022
Study Completion (Actual)
January 9, 2023
Study Registration Dates
First Submitted
April 20, 2021
First Submitted That Met QC Criteria
April 20, 2021
First Posted (Actual)
April 23, 2021
Study Record Updates
Last Update Posted (Estimated)
January 1, 2024
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Gastrointestinal Diseases
- Intestinal Diseases
- Hypersensitivity
- Esophageal Diseases
- Esophagitis
- Duodenal Diseases
- Leukocyte Disorders
- Eosinophilia
- Enteritis
- Gastroenteritis
- Eosinophilic Esophagitis
- Duodenitis
Other Study ID Numbers
- AK002-021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Gastroenteritis
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsRecruitingEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic DuodenitisUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic ColitisUnited States
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic DuodenitisUnited States
-
IRCCS Policlinico S. MatteoItalian Society of Pediatric Allergy & Immunology - Pediatric CentersRecruitingEosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastritis or Gastroenteritis | Eosinophilic Gastrointestinal DisordersItaly
-
Children's Hospital Medical Center, CincinnatiNational Institutes of Health (NIH); Regeneron PharmaceuticalsActive, not recruitingEosinophilic Gastritis | Eosinophilic GastroenteritisUnited States
-
AstraZenecaCompletedEosinophilic Gastritis | Eosinophilic GastroenteritisItaly, Spain, United States, Vietnam, Japan, Netherlands, Ukraine, Poland, Brazil
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic GastroenteritisUnited States
-
Children's Hospital Medical Center, CincinnatiAstraZenecaCompletedEosinophilic Gastritis or GastroenteritisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States